Cat. No.: HY-13632

Exemestane

(Synonyms: FCE 24304; EXE)

7 Cited Publications

Customer Review

Based on 7 publication(s) in Google Scholar

Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.

For research use only. We do not sell to patients.

Purity: 99.97%
CAS No.: 107868-30-4
Formula: C₂₀H₂₄O₂
Molecular Weight:296.40

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Exemestane Chemical Structure

CAS No.: 107868-30-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (7)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Aromatase

All Cytochrome P450 Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC₅₀	0.9 μM Compound: 1, Exemestane	Inhibition of human placental microsome aromatase expressed in human MCF7 cells using [1beta-3H] androstenedione as substrate after 1 hr by liquid scintillation counting Inhibition of human placental microsome aromatase expressed in human MCF7 cells using [1beta-3H] androstenedione as substrate after 1 hr by liquid scintillation counting	[PMID: 25277066]

In Vitro

Exemestane (EXE; 1-1000 nM; 72 hours; hFOB, Saos-2 cells<) treatment significantly increases the number of the cells^[2].
? Exemestane (72 hours) increases alkaline phosphatase activity in hFOB and Saos-2 cells and induces the expression of MYBL2, OSTM1, HOXD11, ADCYAP1R1, and glypican 2 in hFOB cells^[2].
? Exemestane competitively inhibits and time-dependently inactivates of human placental aromatase with K_i of 4.3 nM. Exemestane displaces [³H]5α-dihydrotestosterone from rat prostate androgen receptor with IC₅₀ of 0.9 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

hFOB, Saos-2 cells
Concentration:

1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time:

72 hours
Result:

Induced cell proliferation.

In Vivo

Exemestane (EXE; 20-100 mg/kg; intramuscular injection; once weekly; for 16 weeks) treatment significantly increases the lumbar vertebral and femoral BMD, bending strength of the femur, compressive strength of the fifth lumbar vertebra, and trabecular bone volume. Exemestane significantly reduces an ovariectomy-induced increase in serum pyridinoline and serum osteocalcin. Exemestane causes significant reductions of serum cholesterol and low-density lipoprotein cholesterol^[3].
? Exemestane (20 mg/kg/day s.c.) induces 26% complete (CR) and 18% partial (PR) tumor regressions in rats with 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumors^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Sprague Dawley rats (10-month-old) bearing ovariectomy ^[3]
Dosage:

20 mg/kg, 50 mg/kg, or 100 mg/kg
Administration:

Intramuscular injection; once weekly; for 16 weeks
Result:

Significantly increased the lumbar vertebral and femoral BMD, bending strength of the femur, compressive strength of the fifth lumbar vertebra, and trabecular bone volume.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 107868-30-4
Appearance Solid
Molecular Weight 296.40
Formula C₂₀H₂₄O₂
Color White to off-white
SMILES

C[C@]1([C@](CC2)([H])[C@]3([H])CC(C4=CC(C=C[C@]4(C)[C@@]3([H])CC1)=O)=C)C2=O
Synonyms

FCE 24304; EXE
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (7)

All Cell Proliferation/Viability AssayCell Imaging/StainingFlow CytometryWB

Sort by:

Journal Impact Factor

ACS Cent Sci

An Epigenetic Switch for Sex-Specific Brain Resilience in Stroke: Targeting HDAC2 to Amplify Endogenous Oxytocin Signaling. [Abstract]

2026 Mar 25;12(4):497-523. PMID: 42038487
Mol Oncol

Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer. [Abstract]

2025 Jul 13. PMID: 40652528

Exemestane purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Jul 13. [Abstract]

Cell viability of MDA‐MB‐231 TNBC, MDA‐MB‐436 TNBC, HCC1937 TNBC, MCF7 ER‐positive breast cancer, and MCF10A normal breast cells following 24 h treatment with concentration gradients of Exemestane, with and without 10 μm Olaparib, as determined by MTT assay.

Exemestane purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Jul 13. [Abstract]

Clonogenic survival assay of MDA‐MB‐231, MDA‐MB‐436 cells treated with Exemestane (EXE, 25 μm) and Olaparib (OLAP, 10 μm) alone or in combination (24 h treatment).

Exemestane purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Jul 13. [Abstract]

Cell cycle distribution of MDA‐MB‐231 cells treated with Exemestane (25 μm) and Olaparib (10 μm) alone or in combination, 72 h treatment, as determined by PI staining and flow cytometry.

Exemestane purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Jul 13. [Abstract]

Western blot analysis of DDR activation following Exemestane treatment (25, 50 and 100 μm) for 3 h.

Exemestane purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Jul 13. [Abstract]

RPA1 foci (green) formation in MDA‐MB‐231 cells nuclei following treatment with Exemestane (50 μm, 24 h). Cisplatin (CIS, 50 μm, 24 h) was employed as a positive control. Nuclear staining by DAPI (blue) also included.
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Chem Res Toxicol

Psoralen and Isopsoralen, Two Estrogen -Like Natural Products from Psoraleae Fructus, Induced Cholestasis via Activation of ERK1/2. [Abstract]

2024 May 20;37(5):804-813. PMID: 38646980
J Pharm Biomed Anal

A hydrophobic deep eutectic solvent-based vortex-assisted liquid-liquid microextraction applied for doping control of aromatase inhibitors from equine urine. [Abstract]

2023 Sep 20:234:115583. PMID: 37494867
J Pharm Biomed Anal

Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]

2021 Feb 20:195:113870. PMID: 33453569
Res Sq

2026 Jan 9.

Solvent & Solubility

In Vitro:

DMSO : ≥ 54 mg/mL (182.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3738 mL

16.8691 mL

33.7382 mL

5 mM

0.6748 mL

3.3738 mL

6.7476 mL

10 mM

0.3374 mL

1.6869 mL

3.3738 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Di Salle, E., et al., Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol, 1994. 49(4-6): p. 289-94. [Content Brief]

[2]. Miki, Y, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2004 Sep 1;10(17):5717-23. [Content Brief]

[3]. Goss, P.E., et al., Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res, 2004. 10(17): p. 5717-23. [Content Brief]

[4]. Zaccheo, T., D. Giudici, and E. Di Salle, Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol, 1993. 44(4-6): p. 677-80. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3738 mL	16.8691 mL	33.7382 mL	84.3455 mL
	5 mM	0.6748 mL	3.3738 mL	6.7476 mL	16.8691 mL
	10 mM	0.3374 mL	1.6869 mL	3.3738 mL	8.4345 mL
	15 mM	0.2249 mL	1.1246 mL	2.2492 mL	5.6230 mL
	20 mM	0.1687 mL	0.8435 mL	1.6869 mL	4.2173 mL
	25 mM	0.1350 mL	0.6748 mL	1.3495 mL	3.3738 mL
	30 mM	0.1125 mL	0.5623 mL	1.1246 mL	2.8115 mL
	40 mM	0.0843 mL	0.4217 mL	0.8435 mL	2.1086 mL
	50 mM	0.0675 mL	0.3374 mL	0.6748 mL	1.6869 mL
	60 mM	0.0562 mL	0.2812 mL	0.5623 mL	1.4058 mL
	80 mM	0.0422 mL	0.2109 mL	0.4217 mL	1.0543 mL
	100 mM	0.0337 mL	0.1687 mL	0.3374 mL	0.8435 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Exemestane

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Therapy Drug Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Classic FDA-Approved Drug Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Exemestane

All Cytochrome P450 Isoforms

Biological Activity

Chemical Information

Publications (7)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Exemestane Related Classifications

HY-13632 Related Classifications